NEOSCAN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
May 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEOSCAN is an injectable diagnostic agent approved in 1978 and sponsored by GE HealthCare. The specific indication and mechanism of action are not publicly detailed in available data, but the product operates as an NDA-approved injectable used in diagnostic imaging. This legacy product represents a foundational diagnostic tool in GE's portfolio.
LOE Approaching
As LOE approaches, the brand team is likely operating in stabilization mode with reduced commercial investment and headcount optimization underway.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
Started Oct 2011
42 enrolled
Lung Cancer
Career Relevance
NEOSCAN offers limited career growth opportunities given its approaching LOE and zero linked job openings. Roles on this product are primarily defensive, focused on managing legacy assets, ensuring compliance, and optimizing operational efficiency rather than driving innovation or expansion.
Product Manager
Worked on NEOSCAN at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.